Senolytics — drugs designed to selectively clear "zombie" senescent cells that accumulate with age and drive inflammation and tissue damage — were supposed to be longevity biotech's first real commercial win, and Unity Biotechnology was the company furthest ahead in proving it, until two consecutive Phase 2 trial failures left it laying off staff and searching for a buyer. What Unity's collapse actually reveals is more nuanced than "senolytics don't work" — it's a story about a first-generation approach hitting real limits, while a second wave of more targeted companies keeps building on a genuinely different scientific foundation.
Unity Biotechnology's Two Consecutive Failures
Unity was, for years, the senolytics field's clearest clinical leader — the only company with a drug in human trials while competitors remained preclinical. Its first attempt, UBX0101, targeted painful knee osteoarthritis by inhibiting the p53/MDM2 protein interaction. It advanced through Phase 1 showing early signals of improvement, then missed its primary endpoint for pain and function in a 2020 Phase 2 trial, prompting Unity to discontinue the program and restructure toward ophthalmology instead.
Unity's second attempt, UBX1325, targeted diabetic macular edema through a different mechanism, a BCL-xL inhibitor aimed at senescent cells in the retina. The Phase 2b ASPIRE trial, with results announced in March 2025, produced a result CEO Anirvan Ghosh himself described as maddeningly close: the drug achieved statistical non-inferiority to the standard treatment, aflibercept, at week 24 individually and again at week 36, but missed the trial's specific primary endpoint, non-inferiority averaged across weeks 20 and 24. Ghosh called it "a very, very narrow technical definition" to fail by. The market reacted far less charitably: Unity's stock fell roughly 60% on the news, and by 2026 the company's market capitalization had collapsed to just $13.58 million, with Mizuho downgrading the stock to "Neutral" and a $1 price target. Unity has since laid off staff and is exploring "strategic alternatives," a category that explicitly includes asset sales, licensing deals, mergers, or a full wind-down of the company.
Was Unity's Failure a Verdict on Senolytics Itself?
Researchers closer to the science have consistently framed Unity's struggles as specific to its approach rather than a rejection of the underlying senescent-cell hypothesis. Peter de Keizer, scientific founder of the Netherlands-based Cleara Biotech, said Unity's earlier setback wasn't especially surprising to people in the field, noting the company had "boasted quite a lot from the beginning" about a lead candidate that "wasn't the best one in vitro" to begin with. That's a meaningfully different read than "senolytics failed" — it's closer to "the first company's specific drug wasn't strong enough," which leaves room for a differently designed molecule to succeed where Unity's didn't.
The Companies Betting on More Targeted Approaches
Unity's compounds are generally described as first-generation senolytics — drugs like dasatinib, navitoclax, and UBX0101 that were originally developed for other purposes and repurposed based on the hypothesis that they might also clear senescent cells, often carrying off-target effects that damage healthy cells alongside senescent ones. A newer wave of companies is pursuing more deliberately targeted mechanisms instead. Cleara Biotech's small-molecule candidate uses a different cellular target than Unity's lead compound entirely, and the company secured $45 million in investment from Juvenescence in 2025 specifically for senescent cell clearance work. Velabs Therapeutics, based in Germany, is pursuing antibody drugs rather than small molecules, a structurally different and typically more selective approach. Spain-based Senolytx has gone a step further conceptually, branching into "senomorphic" drugs — treatments that don't kill senescent cells outright but instead work to limit the harmful inflammatory signals those cells send to surrounding tissue, sidestepping some of the off-target risk that comes with actively destroying cells.
Mayo Clinic's Different Bet: Repurposed Generic Drugs
Separate from the venture-backed biotech companies, Mayo Clinic has been running its own Phase 2 clinical trial of dasatinib combined with quercetin (D+Q), a first-generation senolytic combination using existing, already-approved generic drugs rather than a new proprietary compound. That approach trades the higher ceiling of a purpose-built molecule for a much lower-cost, faster-to-test path, and it represents a genuinely different bet on how this field might actually reach patients first, through academic-led repurposing of existing drugs rather than a venture-funded startup's novel pipeline.
The Honest Verdict: A Genuinely Early Field, Not a Dead One
Independent scientific commentary on Unity's setbacks has generally landed on cautious rather than dismissive. Coverage in Science following the UBX1325 result described the broader senolytics field as "not all that encouraging" given the string of underwhelming clinical results, while also noting that the existing pool of senolytic compounds remains "a very mixed bag" with a range of biological activities that complicate clean interpretation of any single trial's outcome. That's a fair summary of where the field actually stands: the first company to reach late-stage trials has stumbled twice, funding for new senolytics bets has gotten harder to raise as a direct result, and the second wave of more targeted companies hasn't yet produced its own late-stage data to prove the more refined approach actually solves the problem Unity ran into.
Senolytics Companies at a Glance
| Company | Approach | Status |
|---|---|---|
| Unity Biotechnology | First-generation small molecules (UBX0101, UBX1325) | Two consecutive Phase 2 failures; exploring wind-down or sale |
| Cleara Biotech | Small molecule, different cellular target than Unity | $45 million investment from Juvenescence in 2025 |
| Velabs Therapeutics | Antibody-based senolytics | Preclinical/early-stage, structurally distinct approach |
| Senolytx | Senomorphic drugs (limit senescent cell effects, don't kill cells) | Early-stage, conceptually different strategy |
| Mayo Clinic (academic) | Repurposed generic drugs (dasatinib + quercetin) | Ongoing Phase 2 trial, low-cost academic-led path |
Frequently Asked Questions
Did Unity Biotechnology's senolytic drug actually fail?
Yes, on a technicality that the CEO himself called narrow. UBX1325 achieved non-inferiority to the standard treatment at week 24 and week 36 individually, but missed the trial's specific primary endpoint measured as an average across weeks 20 and 24. Unity's stock still fell roughly 60% on the news.
Does Unity's failure mean senolytics don't work?
Not necessarily. Researchers at other senolytics companies have described Unity's specific compounds as a relatively crude, first-generation approach compared to newer, more targeted small molecules and antibody-based candidates now in development.
What is the difference between senolytic and senomorphic drugs?
Senolytics are designed to selectively kill senescent cells outright. Senomorphic drugs, a newer approach being pursued by companies like Senolytx, instead work to reduce the harmful inflammatory signals senescent cells send to surrounding tissue without necessarily destroying the cells themselves.
Is Mayo Clinic's dasatinib and quercetin trial different from private biotech companies' drugs?
Yes. Mayo Clinic's Phase 2 trial uses dasatinib and quercetin, both already-approved generic drugs, in combination, rather than a new proprietary compound. This represents a lower-cost, academic-led path to potential senolytic treatment separate from venture-funded biotech pipelines.